News, FDA Approval

FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma-Food and Drug Administration granted approvals to nivolumab and ipilimumab (Opdivo and Yervoy, Bristol-Myers Squibb Co.) in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma.

Source